# 505192472 11/15/2018

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5239241

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

	Name	Execution Date
JA	NSSEN VACCINES & PREVENTION B.V.	11/09/2017

## **RECEIVING PARTY DATA**

Name:	JANSSEN PHARMACEUTICALS, INC.	
Street Address:	1125 TRENTON-HARBOURTON RD.	
City:	TITUSVILLE	
State/Country:	nte/Country: NEW JERSEY	
Postal Code:	08560	

## **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	16191659

## **CORRESPONDENCE DATA**

**Fax Number:** (215)965-1331

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** (215) 965-1330

**Email:** ahyppolite@panitchlaw.com

Correspondent Name: PANITCH SCHWARZE BELISARIO & NADEL LLP

Address Line 1: TWO COMMERCE SQUARE

Address Line 2: 2001 MARKET STREET, SUITE 2800
Address Line 4: PHILADELPHIA, PENNSYLVANIA 19103

ATTORNEY DOCKET NUMBER:	688097-156U1
NAME OF SUBMITTER:	AMBER HYPPOLITE
SIGNATURE:	/AH/
DATE SIGNED:	11/15/2018

## **Total Attachments: 2**

source=Executed Intercompany Assignment - JVP to JPharm (01167327xC4DAF)#page1.tif source=Executed Intercompany Assignment - JVP to JPharm (01167327xC4DAF)#page2.tif

PATENT 505192472 REEL: 047514 FRAME: 0705

0281 WO 00 ORD / CRU5206WOPCT 0281 US 00 ORD / CRU5206USNP

#### General Assignment

WHEREAS, JANSSEN VACCINES & PREVENTION B.V., having its place of business at Archimedesweg 4, 2333 CN Leiden, the Netherlands (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

#### **ExPEC glycoconjugate vaccine formulations**

for which on 24 October 2017, i) International Patent Application no. PCT/EP2017/077123 was filed at the European Patent Office as Receiving Office, and ii) US patent application no. 15/792,242 was filed with the United States Patent and Trademark Office.

WHEREAS, JANSSEN PHARMACEUTICALS, INC., having its place of business at 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560, USA (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from the 24th October 2017.

Page 1 of 2

Page 2 of 2

**RECORDED: 11/15/2018**